Cancer research

Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 3, 2022

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.
  • We are encouraged by the continued clinical progress across our pipeline, said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • In September, Bicycle announced top-line results from the Phase I dose escalation portion of its Phase I/II trial of BT5528, a Bicycle Toxin Conjugate (BTC) targeting EphA2, in patients with advanced solid tumors.
  • In June 2022, Bicycle announced the dosing of the first patient in the Phase II dose expansion portion of the Phase I/II trial.

NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3

Retrieved on: 
Wednesday, November 2, 2022

As such, our scientific advisory board brings diverse, world class expertise across the fundamental disciplines responsible for decision-making in oncology.

Key Points: 
  • As such, our scientific advisory board brings diverse, world class expertise across the fundamental disciplines responsible for decision-making in oncology.
  • For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter .
  • This press release contains certain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995.
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.

Normunity Announces $65 Million Series a Financing to Expand the Frontier of Precision Immuno-Oncology With Immune Normalizer Therapies

Retrieved on: 
Tuesday, October 25, 2022

Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced its launch and Series A financing of $65 million.

Key Points: 
  • Normunity, Inc ., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced its launch and Series A financing of $65 million.
  • Normunitys new class of agents, called immune normalizers, target previously undiscovered mechanisms of immune disruption in cancer.
  • The normal immune system is a powerful anti-cancer force, and effective immune-stimulating strategies can result in long-lasting cancer remissions, even cures.
  • The Series A financing will enable Normunity to advance its emerging pipeline of immune normalizers into the clinic.

Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Retrieved on: 
Monday, October 17, 2022

Yescarta is now the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.

Key Points: 
  • Yescarta is now the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common sub-type of non-Hodgkin lymphoma (NHL), representing around 30% of cases.
  • Yescarta was first approved in Europe in 2018 and is currently indicated for five types of blood cancer: Diffuse Large B-Cell Lymphoma (DLBCL); Large B-Cell Lymphoma (LBCL); High-Grade B-Cell Lymphoma (HGBL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); and Follicular Lymphoma (FL).
  • Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022

Retrieved on: 
Tuesday, October 18, 2022

HOUSTON, Oct. 18, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, announced that results from a preclinical murine study of tegavivint in beta-catenin activated hepatocellular carcinoma (HCC) will be featured in a poster presentation and discussion session at the 34th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) Symposium (ENA 2022). ENA 2022 is being held October 26-28, 2022, in Barcelona, Spain.

Key Points: 
  • Increased expression of beta-catenin and TBL1 are associated with metastasis and poor prognosis in a broad range of tumor types, including HCC.
  • Up to 50% of HCC patients have tumors driven by activating beta-catenin and canonical Wnt pathway mutations.
  • Additionally, in mice with established tumors, tegavivint treatment increased CD3+ T-lymphocyte tumor infiltration, with prominent increases in intratumoral CD8+ T-cells.
  • Iterion is currently advancing multiple clinical programs investigating tegavivint in cancer indications where nuclear beta-catenin overexpression is a known factor.

First U.S. CLIA Lab Implements Alpenglow's 3D Spatial Biology Platform Extending AI-Enabled Pathology to 3D

Retrieved on: 
Monday, October 17, 2022

CorePlus was the first U.S. lab to implement artificial intelligence (AI) based tools for prostate cancer detection to support pathologists in providing accurate diagnoses and is leading the industry again with Alpenglow's AI-enabled 3D spatial biology platform.

Key Points: 
  • CorePlus was the first U.S. lab to implement artificial intelligence (AI) based tools for prostate cancer detection to support pathologists in providing accurate diagnoses and is leading the industry again with Alpenglow's AI-enabled 3D spatial biology platform.
  • "We are excited to be making this transformational leap forward in pathology," said Mariano de Socarraz, Founder and CEO at CorePlus.
  • Alpenglow's 3D offering includes an end-to-end platform solution for enabling whole-tissue digital imaging and analysis.
  • Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues.

Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program

Retrieved on: 
Monday, October 10, 2022

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in the Journal of Medicinal Chemistry.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in the Journal of Medicinal Chemistry.
  • The article, titled Discovery of BT8009: a Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer is available at the publications section of the Bicycle website at this link .
  • The pre-clinical data published in the Journal of Medicinal Chemistry describe the discovery of our clinical-stage Bicycle Toxin Conjugate candidate targeting Nectin-4 expressing tumors, said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics.
  • Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics.

Bionano Genomics Announces Publication of Study from Sorbonne Université Showing that WGS Identified only 63% of Structural Variations that OGM Detected in Liver Cancer

Retrieved on: 
Tuesday, October 4, 2022

The workflow also allowed researchers to compare OGM to WGS, and they reported that, in this study, of all SVs detected using OGM, only 63% were also detected by WGS.

Key Points: 
  • The workflow also allowed researchers to compare OGM to WGS, and they reported that, in this study, of all SVs detected using OGM, only 63% were also detected by WGS.
  • OGM revealed a median of 1.4 times more SVs than WGS, ranging from classical tandem duplications to complex tumor initiating cells (TICs) with multiple template-switching events.
  • Cancer is often thought of as a disease of structural variation, and this study illustrates how OGM has the potential to help unravel the complex mechanisms involved in oncogenesis.
  • The Companys mission is to transform the way the world seesthe genome through OGM solutions, diagnostic services and software.

Henry Schein’s Practice Pink Program Supports Organizations Dedicated to Cancer Research, Prevention, and Awareness

Retrieved on: 
Monday, October 3, 2022

Henry Schein, Inc. (Nasdaq: HSIC) today announced the annual launch of its Practice Pink program supporting nonprofit organizations dedicated to cancer research and prevention.

Key Points: 
  • Henry Schein, Inc. (Nasdaq: HSIC) today announced the annual launch of its Practice Pink program supporting nonprofit organizations dedicated to cancer research and prevention.
  • Practice Pink is a global initiative of Henry Schein Cares, the Companys global corporate social responsibility program.
  • By offering its customers a variety of pink products, including health care consumables, practice supplies, and apparel, Practice Pink supports important cancer research and prevention efforts.
  • The Practice Pink program supports U.S.-based organizations including the American Cancer Society, Cohen Children's Medical Center of Northwell Health, and Stony Brook Children's Hospital.

Labroots Announces Full Three-Day Agenda for its 10th Annual Cancer Research & Immuno-Oncology Week Event, Held on October 4-6, 2022

Retrieved on: 
Wednesday, September 21, 2022

YORBA LINDA, Calif., Sept. 21, 2022 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is hosting its 10th annual Cancer Research and Immuno-Oncology Week conference on October 4-6, 2022. The three-day content-rich agenda continues to be the go-to-meeting sharing cutting-edge discoveries and novel advancements via invited lectures and thought-provoking discussions to improve the outcomes and treatments of patients with cancer.

Key Points: 
  • Cancer Research & Immuno-Oncology Week offers a prestigious forum for some of the brightest minds in the field to collaborate and share knowledge in emerging topics including cancer research, novel targeted therapies in cancer, immuno-oncology, cell therapy, and cancer research networks, epidemiology and patient advocacy.
  • Use the hashtag #LRcancer to follow the conversation and connect with members of the global Cancer & Oncology Research community!
  • Follow @Cancer_LR on Twitter and @CancerResearchandOncology.LR on Facebook to connect with our specialist Cancer & Oncology writers and stay up to date with the latest news in Cancer & Oncology Research.
  • Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities.